Active substance
Nicorandil
- SFDA 4
- NHS prices 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ADANCOR 10 mg tablet | 10 mg | Tablet · Oral use | 30 Blister | SAR 32.00 | NCE · Prescription | Merck Schweiz AG | Valid |
| ADANCOR 20 mg tablet | 20 mg | Tablet · Oral use | 30 Blister | SAR 57.80 | NCE · Prescription | Merck (Schweiz) AG | Valid |
| ADANCOR 10 mg tablet | 10 mg | Tablet · Oral use | 30 Blister | SAR 32.00 | NCE · Prescription | MERCK SANTE | Withdrawn by MAH · Not Marketed |
| ADANCOR 20 mg tablet | 20 mg | Tablet · Oral use | 30 Blister | SAR 57.80 | NCE · Prescription | MERCK SANTE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CORONARY ARTERY DISEASE
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Nicorandil 10mg tablets | £1.18 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Nicorandil 20mg tablets | £2.32 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- MHRA 21 Jan 2016 Nicorandil (Ikorel): now second-line treatment for angina - risk of ulcer complications
Updated advice on use of nicorandil as second-line treatment for stable angina - some ulcers may progress to complications unless treatment is stopped. - MHRA 11 Dec 2014 Nicorandil: risk of gastrointestinal ulceration
Nicorandil is associated with a risk of gastrointestinal ulceration including perianal ulceration.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.